Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

264 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-06-30

Study Completion Date

2010-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to define and classify antibacterial agents used in Turkey for patients with febrile neutropenia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca

NCT04662892

Febrile Neutropenia Non-myeloid Malignancy

UNKNOWN

Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy

NCT02178475

Chemotherapy-induced Febrile Neutropenia

COMPLETED

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

NCT01459653

Febrile Neutropenia Cancer Breast Cancer +6 more

COMPLETED

Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.

NCT07204522

Febrile Neutropenia

RECRUITING

Early Antibiotic Discontinuation in FUO

NCT02906254

Febrile Neutropenia Hematological Malignancy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Febrile Neutropenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All participants

Participants with febrile neutropenia who received antibacterial treatment per investigator's judgment

Antibacterial agent for the treatment of febrile neutropenia

Intervention Type DRUG

The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Antibacterial agent for the treatment of febrile neutropenia

The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who are 18 years old and above.
* Patients who have undergone allogeneic/autologous or peripheral stem cell transplantation following induction or consolidation treatment due to acute hematological malignancy.
* Patients who have a neutrophil count below 500 cells per cubic millimeter (cells/mm\^3) or below 1000 cells/mm\^3 with an expectancy to rapidly decrease below 500 cells/mm\^3.
* Patients with a body temperature more than or equal to (≥)38.3 degrees Celsius (101 degrees Fahrenheit) on single oral measurement or detected ≥38.0 degrees Celsius for at least an hour and thus started on antibacterial treatment will be included in the trial.